FDA warned online seller Amazing Meds over unapproved compounded retatrutide and a misleading "same as Ozempic/Wegovy" semaglutide claim.
What happened
FDA reviewed the company's website, https://amazing-meds.com, in August 2025 and found it offering compounded drug products including retatrutide and semaglutide. FDA said the compounded retatrutide products do not qualify for the exemptions that let compounders skip drug approval, because retatrutide is not the subject of a USP monograph, is not part of an FDA-approved drug, and is not on either federal list of bulk substances allowed for compounding. FDA also said the website claim "Compounded semaglutide (same as Ozempic/Wegovy)" is false or misleading because compounded drugs are not FDA-approved.
What FDA found
The company sold compounded retatrutide, a new drug, without an FDA-approved application, which the law requires before a new drug can be sold across state lines.
FDCA sections 505(a) and 301(d) [21 U.S.C. §§ 355(a), 331(d)]The retatrutide was made from a bulk drug substance that is not allowed under the compounding exemptions — it has no USP or NF monograph, is not part of an approved drug, and is on neither the 503A nor 503B bulk substances list — so the products lose those exemptions.
FDCA sections 503A(b)(1)(A)(i) and 503B(a)(2)(A)(i) [21 U.S.C. §§ 353a(b)(1)(A)(i), 353b(a)(2)(A)]The retatrutide products' labeling does not give adequate directions for use, and adequate directions cannot be written for a layperson to use them safely.
FDCA section 502(f)(1) [21 U.S.C. § 352(f)(1)]The company introduced or delivered misbranded drugs into interstate commerce.
FDCA section 301(a) [21 U.S.C. § 331(a)]The website claim "Compounded semaglutide (same as Ozempic/Wegovy)" suggests the product is the same as an FDA-approved drug when it is not, making the labeling and promotion false or misleading.
FDCA sections 502(a) and 502(bb) [21 U.S.C. §§ 352(a), 352(bb)]
What FDA wants
FDA tells the company to take immediate action, including stopping the misleading semaglutide language, and to send a written response within 15 working days describing the specific corrective steps taken, how recurrence will be prevented, and supporting documentation, or to explain why the products are not in violation.
Who should pay attention
- telehealth and online sellers of compounded weight-loss drugs
- compounding pharmacies and outsourcing facilities using bulk drug substances
- brands and platforms whose products or services are linked to compounded GLP-1 drugs
This is a summary. Read the original letter on fda.gov.